These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 17493049)

  • 21. Neuropsychiatric Adverse Effects of Amphetamine and Methamphetamine.
    Harro J
    Int Rev Neurobiol; 2015; 120():179-204. PubMed ID: 26070758
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stepping through treatment: reflections on an adaptive treatment strategy among methamphetamine users with depression.
    Kay-Lambkin FJ; Baker AL; McKetin R; Lee N
    Drug Alcohol Rev; 2010 Sep; 29(5):475-82. PubMed ID: 20887570
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characteristics and harms associated with injecting versus smoking methamphetamine among methamphetamine treatment entrants.
    McKetin R; Ross J; Kelly E; Baker A; Lee N; Lubman DI; Mattick R
    Drug Alcohol Rev; 2008 May; 27(3):277-85. PubMed ID: 18368609
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Depression ratings, reported sexual risk behaviors, and methamphetamine use: latent growth curve models of positive change among gay and bisexual men in an outpatient treatment program.
    Jaffe A; Shoptaw S; Stein J; Reback CJ; Rotheram-Fuller E
    Exp Clin Psychopharmacol; 2007 Jun; 15(3):301-7. PubMed ID: 17563217
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Methamphetamine abuse.
    Winslow BT; Voorhees KI; Pehl KA
    Am Fam Physician; 2007 Oct; 76(8):1169-74. PubMed ID: 17990840
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cognitive Deficits in Methamphetamine Users: How Strong is The Evidence?
    Proebstl L; Kamp F; Koller G; Soyka M
    Pharmacopsychiatry; 2018 Nov; 51(6):243-250. PubMed ID: 29334687
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An exploratory analysis of neurocognition in methamphetamine-induced psychotic disorder and paranoid schizophrenia.
    Jacobs E; Fujii D; Schiffman J; Bello I
    Cogn Behav Neurol; 2008 Jun; 21(2):98-103. PubMed ID: 18541986
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Methamphetamine use and dental disease: results of a pilot study.
    Cretzmeyer M; Walker J; Hall JA; Arndt S
    J Dent Child (Chic); 2007; 74(2):85-92. PubMed ID: 18477425
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Electrocardiographic abnormalities in methamphetamine abusers.
    Haning W; Goebert D
    Addiction; 2007 Apr; 102 Suppl 1():70-5. PubMed ID: 17493055
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neurocognitive and neuroimaging evidence of behavioural dysregulation in human drug addiction: implications for diagnosis, treatment and prevention.
    Yücel M; Lubman DI
    Drug Alcohol Rev; 2007 Jan; 26(1):33-9. PubMed ID: 17364834
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Methamphetamine-associated difficulties in cognitive control allocation may normalize after prolonged abstinence.
    Stock AK; Rädle M; Beste C
    Prog Neuropsychopharmacol Biol Psychiatry; 2019 Jan; 88():41-52. PubMed ID: 29953935
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ubiquitin-immunoreactive structures in the midbrain of methamphetamine abusers.
    Quan L; Ishikawa T; Michiue T; Li DR; Zhao D; Oritani S; Zhu BL; Maeda H
    Leg Med (Tokyo); 2005 May; 7(3):144-50. PubMed ID: 15847821
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug court treatment for methamphetamine dependence: treatment response and posttreatment outcomes.
    Marinelli-Casey P; Gonzales R; Hillhouse M; Ang A; Zweben J; Cohen J; Hora PF; Rawson RA;
    J Subst Abuse Treat; 2008 Mar; 34(2):242-8. PubMed ID: 17596903
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Technology and innovation in the psychosocial treatment of methamphetamine use, risk and dependence.
    Kay-Lambkin FJ
    Drug Alcohol Rev; 2008 May; 27(3):318-25. PubMed ID: 18368614
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Contingency management: an evidence-based component of methamphetamine use disorder treatments.
    Roll JM
    Addiction; 2007 Apr; 102 Suppl 1():114-20. PubMed ID: 17493060
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The NIDA Methamphetamine Clinical Trials Group: a strategy to increase clinical trials research capacity.
    Elkashef A; Rawson RA; Smith E; Pearce V; Flammino F; Campbell J; Donovick R; Gorodetzky C; Haning W; Mawhinney J; McCann M; Weis D; Williams L; Ling W; Vocci F
    Addiction; 2007 Apr; 102 Suppl 1():107-13. PubMed ID: 17493059
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug abstinence and cognitive control in methamphetamine-dependent individuals.
    Salo R; Nordahl TE; Galloway GP; Moore CD; Waters C; Leamon MH
    J Subst Abuse Treat; 2009 Oct; 37(3):292-7. PubMed ID: 19339145
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Methamphetamine enhances the development of schizophrenia in first-degree relatives of patients with schizophrenia.
    Li H; Lu Q; Xiao E; Li Q; He Z; Mei X
    Can J Psychiatry; 2014 Feb; 59(2):107-13. PubMed ID: 24881129
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adaptation of brain glutamate plus glutamine during abstinence from chronic methamphetamine use.
    Ernst T; Chang L
    J Neuroimmune Pharmacol; 2008 Sep; 3(3):165-72. PubMed ID: 18521756
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Major physical and psychological harms of methamphetamine use.
    Darke S; Kaye S; McKetin R; Duflou J
    Drug Alcohol Rev; 2008 May; 27(3):253-62. PubMed ID: 18368606
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.